Impax Pharmaceuticals

Impax Pharmaceuticals was the branded specialty division of Impax Laboratories, a company primarily focused on central nervous system (CNS) disorders. The company gained significant recognition for its development of Rytary, an extended-release oral formulation of carbidopa and levodopa designed to treat Parkinson's disease. In May 2018, Impax Laboratories completed a transformative merger with Amneal Pharmaceuticals, resulting in the transition of its portfolio to the combined Amneal entity. Beyond its branded CNS products, the company maintained a robust generic drug business known for complex formulations and controlled-release technologies. Its pipeline included advanced candidates like IPX203, which continues to be developed for Parkinson's disease under the Amneal banner. The company's legacy is defined by its expertise in drug delivery systems that improve the pharmacokinetic profiles of established molecules.